Mark Goodfield

3.6k total citations
81 papers, 2.1k citations indexed

About

Mark Goodfield is a scholar working on Rheumatology, Immunology and Dermatology. According to data from OpenAlex, Mark Goodfield has authored 81 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Rheumatology, 34 papers in Immunology and 27 papers in Dermatology. Recurrent topics in Mark Goodfield's work include Systemic Lupus Erythematosus Research (23 papers), Psoriasis: Treatment and Pathogenesis (15 papers) and Dermatology and Skin Diseases (13 papers). Mark Goodfield is often cited by papers focused on Systemic Lupus Erythematosus Research (23 papers), Psoriasis: Treatment and Pathogenesis (15 papers) and Dermatology and Skin Diseases (13 papers). Mark Goodfield collaborates with scholars based in United Kingdom, Canada and United States. Mark Goodfield's co-authors include Alison Layton, W.J. Cunliffe, E. G. V. Evans, Paul Emery, N.R. Rowell, J A Davies, Sally H. Ibbotson, Karen Bowden, Katy Davison and Edward J. Wood and has published in prestigious journals such as The Lancet, PEDIATRICS and Annals of the Rheumatic Diseases.

In The Last Decade

Mark Goodfield

80 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Goodfield United Kingdom 27 863 768 725 369 363 81 2.1k
Sylvia Hsu United States 23 1.0k 1.2× 1.1k 1.5× 460 0.6× 326 0.9× 613 1.7× 142 2.2k
B. Crickx France 28 895 1.0× 371 0.5× 1.0k 1.4× 874 2.4× 646 1.8× 118 3.1k
Miklós Sárdy Hungary 27 563 0.7× 293 0.4× 691 1.0× 454 1.2× 1.0k 2.8× 126 2.3k
María Galindo-Izquierdo Spain 30 171 0.2× 853 1.1× 902 1.2× 316 0.9× 302 0.8× 114 2.6k
Charles Camisa United States 28 757 0.9× 399 0.5× 627 0.9× 578 1.6× 1.1k 3.0× 116 2.7k
K. Tamaki Japan 16 364 0.4× 255 0.3× 539 0.7× 234 0.6× 267 0.7× 59 1.5k
Sinisa Savic United Kingdom 33 240 0.3× 1.3k 1.6× 649 0.9× 237 0.6× 168 0.5× 142 3.1k
Hong‐Shang Hong Taiwan 19 693 0.8× 227 0.3× 513 0.7× 327 0.9× 605 1.7× 67 2.4k
M.‐S. Doutre France 20 405 0.5× 203 0.3× 479 0.7× 317 0.9× 437 1.2× 131 1.4k
Yoko Kano Japan 28 568 0.7× 605 0.8× 1.7k 2.3× 514 1.4× 616 1.7× 74 2.8k

Countries citing papers authored by Mark Goodfield

Since Specialization
Citations

This map shows the geographic impact of Mark Goodfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Goodfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Goodfield more than expected).

Fields of papers citing papers by Mark Goodfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Goodfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Goodfield. The network helps show where Mark Goodfield may publish in the future.

Co-authorship network of co-authors of Mark Goodfield

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Goodfield. A scholar is included among the top collaborators of Mark Goodfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Goodfield. Mark Goodfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Isabelle L, Sarah Brown, Catherine Fernandez, et al.. (2022). Comparison of ALitretinoin with PUVA as the first-line treatment in patients with severe chronic HAnd eczema (ALPHA): study protocol for a randomised controlled trial. BMJ Open. 12(2). e060029–e060029. 2 indexed citations
2.
Smith, Isabelle L, Jane Nixon, Fiona Cowdell, et al.. (2016). Treatment of severe, chronic hand eczema: results from a UK-wide survey. Clinical and Experimental Dermatology. 42(2). 185–188. 7 indexed citations
3.
Reich, Kristian, Jennifer Soung, Melinda Gooderham, et al.. (2016). THU0439 52-Week Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate To Severe Psoriasis: Results from The Liberate Study. Annals of the Rheumatic Diseases. 75. 349–349. 2 indexed citations
4.
Thaçi, Diamant, Gil Yosipovitch, Kim Papp, et al.. (2015). Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis : results from the ESTEEM 1 and 2 trials. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
5.
Vital, Edward M, Miriam Wittmann, Md Yuzaiful Md Yusof, et al.. (2015). Brief Report: Responses to Rituximab Suggest B Cell–Independent Inflammation in Cutaneous Systemic Lupus Erythematosus. Arthritis & Rheumatology. 67(6). 1586–1591. 78 indexed citations
6.
Palmou‐Fontana, Natalia, Helena Marzo‐Ortega, Zoe Ash, et al.. (2011). Linear Pitting and Splinter Haemorrhages Are More Commonly Seen in the Nails of Patients with Established Psoriasis in Comparison to Psoriatic Arthritis. Dermatology. 223(4). 370–373. 17 indexed citations
7.
Goodfield, Mark, et al.. (2009). Basement membrane changes in lichen planopilaris. Journal of the European Academy of Dermatology and Venereology. 23(11). 1289–1293. 3 indexed citations
8.
Ingham, Eileen, et al.. (2009). Expression of hair follicle stem cells detected by cytokeratin 15 stain: implications for pathogenesis of the scarring process in cutaneous lupus erythematosus. British Journal of Dermatology. 160(6). 1188–1196. 35 indexed citations
9.
Sommer, Sabine, et al.. (2004). Systemic lupus erythematosus or infection with HIV, or both?. Clinical and Experimental Dermatology. 29(4). 393–395. 9 indexed citations
10.
11.
Goodfield, Mark, Katy Davison, & Karen Bowden. (2004). Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE).. Journal of Dermatological Treatment. 15(1). 46–50. 43 indexed citations
12.
Ling, Tsui C., V. Goulden, & Mark Goodfield. (2001). PUVA therapy in lichen aureus. Journal of the American Academy of Dermatology. 45(1). 145–146. 26 indexed citations
13.
Yazıcı, Zihni Açar, et al.. (1998). Does the CDR3 of the Heavy Chain Determine the Specificity of Autoantibodies in Systemic Lupus Erythematosus?. Journal of Autoimmunity. 11(5). 477–483. 4 indexed citations
14.
Bottomley, W.W. & Mark Goodfield. (1995). Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. British Journal of Dermatology. 133(2). 311–314. 19 indexed citations
15.
Ibbotson, Sally H., Alison Layton, J A Davies, & Mark Goodfield. (1995). The effect of aspirin on haemostatic activity in the treatment of chronic venous leg ulceration. British Journal of Dermatology. 132(3). 422–426. 35 indexed citations
16.
Goodfield, Mark. (1994). Skin lesions in psoriasis. Baillière s Clinical Rheumatology. 8(2). 295–316. 11 indexed citations
17.
Goodfield, Mark, et al.. (1994). Investigations of the 'active' edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin. British Journal of Dermatology. 131(6). 808–813. 58 indexed citations
18.
Goodfield, Mark, et al.. (1994). Multiple dermatofibromata developing during pregnancy. Clinical and Experimental Dermatology. 19(1). 59–60. 17 indexed citations
19.
Bottomley, W. & Mark Goodfield. (1994). A pathogenic role for endothelin in Raynaud's phenomenon?. Acta Dermato Venereologica. 74(6). 433–434. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvia Hsu Breakdown of academic impact, for papers by B. Crickx Breakdown of academic impact, for papers by Miklós Sárdy Breakdown of academic impact, for papers by María Galindo-Izquierdo Breakdown of academic impact, for papers by Charles Camisa Breakdown of academic impact, for papers by K. Tamaki Breakdown of academic impact, for papers by Sinisa Savic Breakdown of academic impact, for papers by Hong‐Shang Hong Breakdown of academic impact, for papers by M.‐S. Doutre Breakdown of academic impact, for papers by Yoko Kano
Rankless by CCL
2026